Prof. Chen is engaged in the study of pathogenesis and treatment of leukemia. She initiated Leukemia Genomic Anatomy Project and has obtained a series of novel molecular biomarkers and targets for disease classification, prognosis and targeted therapy. She led the team to innovate the synergistic targeted therapy for acute promyelocytic leukemia (APL) with all-trans retinoic acid and arsenic trioxide, and has turned APL from a fatal malignancy to a curable disease, which has been extended to other types of leukemia. Recently, the exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen (LCAR-B38M) in relapsed/refractory multiple myeloma led by her has achieved significant effects. The above research work has profoundly promoted the development of hematology in China and exerted a considerable influence in international medical communities.